Day: June 4, 2020

VENICE, Fla., June 04, 2020 (GLOBE NEWSWIRE) — CyberloQ Technologies Inc. (“CyberloQ” or the “Company”) (OTC: CLOQ), a provider of advanced authentication algorithms and geofencing capabilities for data control, today provides details of its licensing revenue model created through the Company’s collaboration with Transact Payments Malta Ltd. (“TPML”), a division of Transact Payments Ltd. (“TPL”) located in Europe.  CyberloQ’s strategic partnership with TPL integrates CyberloQ’s customizable data security, which includes geofencing protection, to provide an additional layer of security to TPML partners. This collaboration provides CyberloQ new revenue channels that leverage TPL’s vast, existing network of program managers, processors and clients of the company’s custom card program.The models below demonstrate...

SAN DIEGO, June 04, 2020 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual event format for 2020, known as BIO Digital, from June 8-12, 2020. Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will participate in a panel discussion titled Redefining BioPharma in a Female-Forward World and will separately provide a company presentation. Both the panel discussion and company presentation will be available on-demand during the conference for all registered virtual event attendees.Event registration is available at https://www.bio.org/events/bio-digital/registration.Following the conclusion of the event, a recording of Ms. Johnson’s presentation and a video...

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has regained the worldwide rights to JTX-8064 from Bristol Myers Squibb. JTX-8064 is a highly-selective, potential first-in-class antibody that targets the Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) on macrophages, and was licensed to Celgene in July 2019. As part of its Celgene integration process, Bristol Myers Squibb is streamlining its pipeline and addressing areas of overlap. As a result, Bristol Myers Squibb notified Jounce that the JTX-8064 License Agreement is being terminated.   “We are thrilled to regain the rights to JTX-8064 and we view this as a significant opportunity for...

EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at two upcoming investor conferences in June.Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 2:10 p.m. ETRaymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ETA live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.About Gritstone Oncology Gritstone...

Decades of experience in drug development and finance to support company advancing novel treatments for rare dermatologic diseasesWoodcliff Lake, NJ, June 04, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced the appointment of Gianluca Pirozzi, M.D., Ph.D. and Edward J. Sitar to its Board of Directors.“We are pleased to welcome Dr. Pirozzi and Mr. Sitar to the Board as we continue to advance innovative clinical research evaluating novel treatments for rare dermatologic diseases with limited options,” said John Koconis, Chief Executive Officer of Timber. “Their experience supporting the success of public...

EDEN PRAIRIE, Minn., June 04, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced Children’s Hospital of The King’s Daughters (CHKD) in Norfolk, Virginia has initiated ultrafiltration therapy using the Aquadex SmartFlow™ system.“Following FDA clearance and the launch of the Aquadex SmartFlow system in the first quarter, we continue to see strong interest from pediatric hospitals,” said John Erb, chairman and CEO of CHF Solutions.  “We are proud to work with the medical team at Children’s Hospital of The King’s Daughters to bring this simple, gentle and smart therapy to its patients suffering from fluid overload.”“We will use this ultrafiltration therapy to accommodate the needs of children that require fluid removal without the added risk of hemodialysis and to meet the needs of ICU patients with heart disease that...

GREENWICH, Conn., June 04, 2020 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCO) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) today announced the following net asset value (“NAV”) estimate as of May 31, 2020.Management’s unaudited estimate of the range of our NAV per share of our common stock as of May 31, 2020 is between $2.87 and $2.97. This estimate is not a comprehensive statement of our financial condition or results for the month ended May 31, 2020. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ended June 30, 2020 may differ materially from this estimate, which is given only as of May 31, 2020.We believe that the COVID-19 pandemic represents an extraordinary...

Leiðrétting felst eingöngu í breytingu á fyrirsögn tilkynningar.Í dag staðfesti Hæstiréttur niðurstöðu áfrýjaðs dóms Landsréttar í máli Norðurturnsins hf. gegn Eignarhaldsfélaginu Smáralind ehf. og Kópavogsbæ, í máli nr. 32/2019.Með dóminum var viðurkennd kvöð sem veitti Norðurturninum hf. rétt til nýtingar bílastæða á lóðinni við Hagasmára 1. Með sama hætti á Eignarhaldsfélagið Smáralind ehf. rétt til nýtingar bílastæða á lóðinni við Hagasmára 3, sem er í eigu Norðurturnsins hf. Eignarhaldsfélaginu Smáralind ehf. og Kópavogsbæ var gert að greiða málskostnað að fjárhæð 1.000.000 kr.  Í fyrri tilkynningum frá félaginu hefur komið fram að dómsmálið hafi óveruleg fjárhagsleg áhrif á Reginn og dótturfélög enda ekki höfð uppi fjárkrafa í málinu. Þá hefur málareksturinn ekki haft áhrif á uppbyggingaráform á svæði Smárans vestan Reykjanesbrautar...